Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

Marvaso, Giulia; Volpe, Stefania; Pepa, Matteo; Zaffaroni, Mattia; Corrao, Giulia; Augugliaro, Matteo; Nolè, Franco; Cobelli, Ottavio De; Jereczek‐Fossa, Barbara Alicja

doi:10.2147/cmar.s321136

Cited by 3 publications

(1 citation statement)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the term "oligometastasis" denotes a condition characterized by cancer's dissemination to a limited number of body sites-usually fewer than five [2][3][4][5]. The oligometastatic condition is most commonly observed in patients with solid tumors, such as lung, prostate, and breast cancers [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Marvaso,

Mastroleo,

Corrao

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

The term “oligometastasis” represents a relatively novel idea, which denotes a condition characterized by cancer dissemination with a limited number of lesions (usually fewer than five). The aim of the present study is to report a bibliometric analysis of the oligometastatic disease/state, incorporating all relevant studies on the topic for more than 20 years. The research strategy included at least one the terms “Oligmetastases”, “Oligometastasis”, “Oligometastatic”, “Oligoprogression, “Oligoprogressive”, “Oligorecurrent”, or “Oligorecurrency” in the title, abstract, and/or keywords. All English-language documents from 1 January 1995 (the year of the earliest available document in Scopus) to 31 December 2022 were considered for the analysis. R code (R version 4.2.0) with R Studio (version 2022.12.0-353) and the Bibliometrix package (version 4.0.1) were used for the analysis. A total of 3304 documents, mainly articles (n = 2083, 63.0%) and reviews (n = 813, 24.6%), were collected from 1995 to 2022. The average annual growth rate of literature on the topic was 26.7%. Overall 15,176 authors published on the topic, with an average of eight authors/publication. From 1995, 69 countries contributed to the literature, with the USA and Italy being the top contributors. Among all keywords used by authors, the top three were oligometastases (19%), SBRT (18%), and radiation therapy (8%). Themes regarding “locoregional treatment”, “organ motion”, and “immunotherapy” were the most recent trend topics, mainly developed from 2019 to 2022, while “high-dose chemotherapy”, “whole-brain radiotherapy”, and “metastatic breast cancer” saw their main development during 2009–2018. Our study shows the exceptionally flourishing scientific production on the oligometastatic state, summarizing the most influential studies and highlighting the future developments and interests. This analysis will serve as a benchmark to identify this area for the attention of researchers worldwide and contribute to the increasing scientific work.

show abstract

Section: Introductionmentioning

confidence: 99%

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Marvaso,

Mastroleo,

Corrao

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone‐sensitive prostate cancer

Gong,

Janes,

Trustram Eve

et al. 2024

Cancer

View full text Add to dashboard Cite

BackgroundThis study was conducted to better characterize the epidemiology, clinical outcomes, and current treatment patterns of de novo oligometastatic hormone‐sensitive prostate cancer (omHSPC) in the United States Veterans Affairs Health Care System.MethodsIn this observational retrospective cohort study, 400 de novo metastatic hormone‐sensitive PC (mHSPC) patients diagnosed from January 2015 to December 2020 (follow‐up through December 2021) were randomly selected. omHSPC was defined as five or less total metastases (excluding liver) by conventional imaging. Kaplan–Meier methods estimated overall survival (OS) and castration‐resistant prostate cancer (CRPC)‐free survival from mHSPC diagnosis date and a log‐rank test compared these outcomes by oligometastatic status.ResultsTwenty percent (79 of 400) of de novo mHSPC patients were oligometastatic. Most baseline characteristics were similar by oligometastatic status; however, men with non‐omHSPC had higher median prostate‐specific antigen at diagnosis (151.7) than omHSPC (44.1). First‐line (1L) novel hormonal therapy was similar between groups (20%); 1L chemotherapy was lower in omHSPC (5%) versus non‐omHSPC (14%). More omHSPC patients received metastasis‐directed therapy/prostate radiation therapy (14%) versus non‐omHSPC (2%). Median OS and CRPC‐free survival (in months) were higher in omHSPC versus non‐omHSPC (44.4; 95% confidence interval [CI], 33.9–not estimated vs. 26.2; 95% CI, 20.5–32.5, p = .0089 and 27.6; 95% CI, 22.1–37.2 vs. 15.3; 95% CI, 12.8–17.9, p = .0049), respectively.ConclusionsApproximately 20% of de novo mHSPC were oligometastatic, and OS was significantly longer in omHSPC versus non‐omHSPC. Although potentially “curative” therapy use was higher in omHSPC versus non‐omHSPC, the percentages were still relatively low. Future studies are warranted given potential for prolonged responses with multimodal therapy inclusive of systemic and local therapies.

show abstract

Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

Arcos¹,

López-Campos²,

Valcárcel³

et al. 2023

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

Cited by 3 publications

References 78 publications

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone‐sensitive prostate cancer

Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

Contact Info

Product

Resources

About